A new clinical trial at The Ohio State University's Wexner Medical Center could change how doctors treat breast cancer.
The trial involves targeted treatment going after an aggressive form of breast cancer, and it could be a game-changer.
"This could really revolutionize the way women are treated with breast cancer," said Dr. Erin Macrae, of the OSU Comprehensive Breast Center.
Macrae is leading the clinical trial, focusing on two new drugs to target specific ways triple negative breast cancer grows and spreads.
Currently, for triple negative breast cancer patients, chemotherapy is the only option of treatment.
"Most of the time, women have to come into the hospital, get their IVs hooked up, and if they can take their medications at home in the comfort of their normal surroundings, it could really improve their quality of life," Macrae said.
It could change the treatment, and help patients avoid the side effects.
"With IV chemotherapy, women can lose their hair, have other side effects. With these meds, much less toxic, that's huge. Women can really live normal, regular lives," she said.
OSU is the lead on the nationwide study, which is expected to begin soon.
Doctors are looking for women with advanced triple negative breast cancer to participate.